{"id":"W3028809236","doi":"10.1200/jco.2020.38.15_suppl.5602","title":"HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Castration; Urology; Testosterone (patch); Leuprorelin; Clinical endpoint; Internal medicine; Prostate; Hormone antagonist; Randomized controlled trial; Endocrinology; Antagonist; Cancer; Gynecology; Gonadotropin-releasing hormone; Hormone; Luteinizing hormone; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001682988,0.001301241,0.001620732,0.0003700125,0.0002237193,0.0007782424,0.0007469075,0.001044719,0.008621965],"category_scores_gemma":[0.001397107,0.0003908697,0.001440041,0.0003069882,0.000755072,0.000631802,0.0003584949,0.001807909,0.0009312247],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000608775,"about_ca_system_score_gemma":0.0008075686,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007141005,"about_ca_topic_score_gemma":0.001963499,"domain_scores_codex":[0.9995228,0.0003067633,0.00001592605,0.00006108234,0.00004584474,0.00004747349],"domain_scores_gemma":[0.9992809,0.0002039577,0.0002048735,0.00004227744,0.0000328994,0.0002351717],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9640586,0.004434971,0.001248034,0.0008861234,0.0008539346,0.00006211312,0.00005625256,0.0008089313,0.003953635,0.0002602598,0.003302891,0.02007413],"study_design_scores_gemma":[0.9156532,0.07723394,0.003240122,0.000055942,0.0003637403,0.0001272937,0.00002764942,0.0007481361,0.0004738678,0.0002030107,0.001856998,0.00001623055],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9651952,0.009950371,0.001154259,0.001271726,0.0005968031,0.004274406,0.007051548,0.0003852093,0.01012042],"genre_scores_gemma":[0.9589576,0.005142628,0.003129386,0.002308492,0.0008909627,0.004363401,0.009511664,0.0001123307,0.01558355],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008621965,"threshold_uncertainty_score":0.02884334,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3834256382585731,"score_gpt":0.576770821601796,"score_spread":0.1933451833432229,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}